Literature DB >> 24945236

Respiratory pharmacotherapy use in patients newly diagnosed with chronic obstructive pulmonary disease in a primary care setting in the UK: a retrospective cohort study.

Keele E Wurst1, Amit Shukla, Hana Muellerova, Kourtney J Davis.   

Abstract

This retrospective cohort study aimed to analyze the prescribing practices of general practitioners treating patients with newly diagnosed chronic obstructive pulmonary disease (COPD), and to assess characteristics associated with initial pharmacotherapy. Patients were identified in the General Practice Research Database, a population-based UK electronic medical record (EMR) with data from January 1, 2008 to December 31, 2009. Patient characteristics, prescribed COPD pharmacotherapies (≤12 months before diagnosis and within 3 months following diagnosis), co-morbidities, hospitalizations, and events indicative of a possible COPD exacerbation (≤12 months before diagnosis) were analyzed in 7881 patients with newly diagnosed COPD. Most patients (64.4%) were prescribed COPD pharmacotherapy in the 12 months before diagnosis. Following diagnosis, COPD pharmacotherapy was prescribed within 3 months in 85.0% of patients. Short-acting bronchodilators alone (22.9%) or inhaled corticosteroids + long-acting beta-2 agonists (ICS+LABA, 22.1%) were prescribed most frequently. Compared with other pharmacotherapies, the prevalence of severe airflow limitation was highest in patients prescribed ICS+LABA+long-acting muscarinic antagonists (LAMA). Moderate-to-severe dyspnea was identified most frequently in patients prescribed a LAMA-containing regimen. Patients prescribed an ICS-containing regimen had a higher prevalence of asthma or possible exacerbations recorded in the EMR than those not prescribed ICS. In conclusion, pharmacotherapy prescribed at initial COPD diagnosis varied by disease severity indicators as assessed by airflow limitation, dyspnea, history of asthma, and possible exacerbations. Frequent prescription of COPD pharmacotherapies before the first-recorded COPD diagnosis indicates a delay between obstructive lung disease presentation in primary care practice and assignment of a medical diagnosis.

Entities:  

Keywords:  GOLD strategy; inhaled corticosteroids; long-acting bronchodilators; newly diagnosed COPD; primary care; short-acting bronchodilators

Mesh:

Substances:

Year:  2014        PMID: 24945236     DOI: 10.3109/15412555.2014.922064

Source DB:  PubMed          Journal:  COPD        ISSN: 1541-2563            Impact factor:   2.409


  9 in total

1.  Epidemiology, severity, and treatment of chronic obstructive pulmonary disease in the United Kingdom by GOLD 2013.

Authors:  Mireia Raluy-Callado; Dimitra Lambrelli; Sharon MacLachlan; Javaria Mona Khalid
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2015-05-13

Review 2.  Factors influencing the development of primary care data collection projects from electronic health records: a systematic review of the literature.

Authors:  Marie-Line Gentil; Marc Cuggia; Laure Fiquet; Camille Hagenbourger; Thomas Le Berre; Agnès Banâtre; Eric Renault; Guillaume Bouzille; Anthony Chapron
Journal:  BMC Med Inform Decis Mak       Date:  2017-09-25       Impact factor: 2.796

3.  Blood eosinophilia, use of inhaled corticosteroids, and risk of COPD exacerbations and mortality.

Authors:  Olorunfemi A Oshagbemi; Frits M E Franssen; Dionne C W Braeken; Yvonne Henskens; Emiel F M Wouters; Anke-Hilse Maitland-van der Zee; Andrea M Burden; Frank de Vries
Journal:  Pharmacoepidemiol Drug Saf       Date:  2018-09-28       Impact factor: 2.890

4.  COPD patients' characteristics, usual care, and adherence to guidelines: the Greek UNLOCK study.

Authors:  Ioanna Tsiligianni; Maria Kampouraki; Despo Ierodiakonou; Ioannis Poulonirakis; Polyvios Papadokostakis
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2019-03-01

5.  Changes in COPD inhaler prescriptions in the United Kingdom, 2000 to 2016.

Authors:  Chloe I Bloom; S L Elkin; J K Quint
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2019-01-22

6.  Clinical characteristics and factors associated with triple therapy use in newly diagnosed patients with COPD.

Authors:  Mònica Monteagudo; Miriam Barrecheguren; Iryna Solntseva; Nafeesa Dhalwani; Alison Booth; Alexa Nuñez; Dimitra Lambrelli; Marc Miravitlles
Journal:  NPJ Prim Care Respir Med       Date:  2021-03-22       Impact factor: 2.871

7.  Characteristics of COPD patients according to GOLD classification and clinical phenotypes in the Russian Federation: the SUPPORT trial.

Authors:  Vladimir Arkhipov; Daria Arkhipova; Marc Miravitlles; Andrey Lazarev; Ekaterina Stukalina
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2017-11-03

8.  Asthma-COPD overlap syndrome (ACOS) in primary care of four Latin America countries: the PUMA study.

Authors:  Maria Montes de Oca; Maria Victorina Lopez Varela; Maria E Laucho-Contreras; Alejandro Casas; Eduardo Schiavi; Juan Carlos Mora
Journal:  BMC Pulm Med       Date:  2017-04-21       Impact factor: 3.317

Review 9.  What have we learned from observational studies and clinical trials of mild to moderate COPD?

Authors:  Miriam Barrecheguren; Cruz González; Marc Miravitlles
Journal:  Respir Res       Date:  2018-09-17
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.